98%
921
2 minutes
20
Background: Fulminant hepatic failure manifests a rapid onset, serious complications, and a high mortality, but still there is a possibility of recovery. Once the patient is able to pass a crisis, the liver is able to regenerate completely and regain its normal function. Therefore it is of vital importance to determine the eligible timing for transplantation. Premature surgery might result in a loss of the chance of internal medical treatment and misuse of liver resources, whereas delayed surgery might increase the difficulty of treatment in the preoperative period and the possibility of complications and medical expense, which eventually result in decreased rate of success and survival. This problem remains worldwide how to choose the optional timing of operation.
Methods: Thirty-six patients with severe hepatitis were treated by orthotopic liver transplantation. The distribution of MELD scores in these patients was: 10-19 in 8 patients, 20-29 in 10, 30-39 in 11, and 40 in 7. They were divided into two groups: MELD score <30 and MELD score >or=30. Parameters (1-year survival rate, complications, preoperative use of artificial liver, operative time, volume of bleeding and blood transfusion, and average hospital costs) were examined as prognostic factors after liver transplantation.
Results: The 1-year survival rate of the MELD score <30 group was higher than that of the >or=30 group (77.8% and 33.3%, P=0.007), and the rate of complications in the <30 group was lower (P=0.012). There were no differences in the timing of artificial liver treatment, operative time, operative hemorrhage, and transfusion between the two groups (P=0.742). But the average daily hospital cost in the MELD score >or=30 group was higher (P=0.008).
Conclusion: This study shows that when the MELD score is <30 it may be the optimal time to perform liver transplantation for patients with severe hepatitis.
Download full-text PDF |
Source |
---|
Hepatology
September 2025
Department of Gastroenterology and Hepatology, UT Southwestern, Dallas, TX.
Background: The clinical course and outcomes of alcohol-associated hepatitis (AH) remain poorly understood. Major adverse liver outcomes (MALO) do not capture the added risk of return to drinking (RTD). We examined the natural history of AH and developed a composite endpoint using a contemporary observational cohort of AH.
View Article and Find Full Text PDFLiver Int
October 2025
Hannover Medical School, Department of Diagnostic and Interventional Radiology, Hannover, Germany.
Background And Aims: We aimed to ascertain the prevalence of sarcopenia in patients with primary sclerosing cholangitis (PSC) and to assess the prognostic value as a biomarker for disease outcome.
Methods: We collected data from 224 patients (148 male, 76 female; mean age 41 years) from January 2002 to December 2021, with a confirmed diagnosis of PSC who underwent magnetic resonance imaging (MRI). Muscle mass was quantified at the level of the third lumbar vertebra by measurement of psoas muscle thickness (PMT) and total psoas muscle area (PMA).
PLoS One
September 2025
School of Software, Hunan College of Information, Chang sha, Hunan Province, China.
This research has proposed a new Emotion Recognition in Conversation (ERC) model known as Hierarchical Graph Learning for Emotion Recognition (HGLER), built to go beyond the existing approaches that find it difficult to request long-distance context and interaction across different data types. Rather than simply mixing different kinds of information, as is the case with traditional methods, HGLER uses a 2-part graph technique whereby conversations are represented in a 2-fold manner: one aimed at illustrating how various parts of the conversation relate and another for enhancing learning from various types of data. This dual-graph system can represent multimodal data value for value by exploiting the benefits of each type of data yet tracking their interactions.
View Article and Find Full Text PDFHepatol Commun
September 2025
Department of Internal Medicine, Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Background: Steatotic liver diseases (SLDs) and their subcategories-metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD)-significantly contribute to liver-related and extrahepatic morbidity and mortality. This project aimed to assess the landscape of SLDs and clinically significant fibrosis (CSF) before (2017-2020) and during (2021-2023) the COVID-19 pandemic.
Methods: Using National Health and Nutrition Examination Survey (NHANES) data, we analyzed 8965 prepandemic and 6337 pandemic participants aged ≥18 years.
Infect Dis Ther
September 2025
The Third Clinical Medical College, Qingdao University School of Medicine, Qingdao Municipal Hospital, Qingdao, Shandong, China.
Introduction: Oral nucleos(t)ide analogues (NAs) are widely used in managing hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF). Among first-line therapies, entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are commonly prescribed. However, their comparative efficacy and safety remain unclear in HBV-ACLF.
View Article and Find Full Text PDF